Multiple myeloma trials in Germany

In Germany 64 Also abroad 703

64 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma
Where
Berlin, Chemnitz, Greifswald, Hamburg, Heidelberg, Luebeck, Ulm
Age
18 years and over
People
45
Run by
Universitätsklinikum Hamburg-Eppendorf
See details and how to joinNCT05853965 · EU 2024-511794-30-00
No phaseTaking people
BEAM-MM - β-Hydroxybutyrate-Enhanced Adaptive Immunity in Multiple Myeloma
Where
Hamburg
Age
18 years and over
People
45
Run by
Universitätsklinikum Hamburg-Eppendorf
See details and how to joinNCT07564219
Phase 3Taking people
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Where
Chemnitz, Cologne, Dresden, Hamburg, Hanover, Jena, Luebeck, Mainz, Wuerzburg
Age
18 years and over
People
520 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06679101 · EU 2024-516030-35-00
Phase 3Taking people
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
Where
Greifswald, Luebeck, Wuerzburg
Age
18 years and over
People
1,000 worldwide
Run by
European Myeloma Network B.V.
See details and how to joinNCT06932562 · EU 2024-519827-16-00
Phase 1Taking people
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Where
Cologne, Heidelberg, Wuerzburg
Age
18 years and over
People
187 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06153251 · EU 2023-506003-26-00
No phaseTaking people
Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency
Where
Berlin
Age
18 years and over
People
75 worldwide
Run by
Takeda
See details and how to joinNCT05879757
No phaseNot yet taking people in Germany
Exercise Therapy for Multiple Myeloma Patients
Where
Heidelberg
Age
18 years to 75 years
People
71
Run by
University Hospital Heidelberg
See details and how to joinNCT07388147
No phaseTaking people
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Where
Essen
People
50 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06357754
No phaseTaking people
Fall Risk Assessment and an Exercise Intervention for Prevention of Falls in Multiple Myeloma Patients
Where
Heidelberg
Age
18 years and over
People
60
Run by
University Hospital Heidelberg
See details and how to joinNCT07044427
Phase 2Taking people
GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
Where
Berlin, Chemnitz, Dresden, Duesseldorf, Freiburg im Breisgau, Hamburg, Heidelberg, Kiel, Munich, Wuerzburg
Age
18 years to 70 years
People
160
Run by
University of Heidelberg Medical Center
See details and how to joinNCT05695508 · EU 2024-517382-17-00
No phaseTaking people
GMMG Multiple Myeloma Registry
Where
Berlin, Bielefeld, Bochum, Bonn, Chemnitz, Cologne, Darmstadt, Düsseldorf, Erlangen, Essen, Frankfurt am Main, Giessen, Hagen, Hamburg, Heidelberg, Heilbronn, Homburg, Kaiserslautern, Koblenz, Lebach, Mainz, Mannheim, Marburg, Mönchengladbach, Regensburg, Schwäbisch Hall, Siegburg, Speyer, Trier, Tübingen
Age
18 years and over
People
999
Run by
Prof. Dr. Hartmut Goldschmidt
See details and how to joinNCT07111884
Phase 3Taking people
A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma (GMMG-HD9/DSMM XVIII-trial)
Where
Aachen, Augsburg, Bad Saarow, Bayreuth, Berlin, Bielefeld, Bonn, Braunschweig, Bremen, Chemnitz, Cottbus, Darmstadt, Dessau-Rosslau, Dortmund, Dresden, Duesseldorf, Duisburg, Eschweiler, Essen, Flensburg, Frankfurt, Frankfurt Am Main, Freiburg im Breisgau, Greifswald, Hagen, Halle (Saale), Hamburg, Hannover, Heidelberg, Heilbronn, Homburg, Jena, Kaiserslautern, Karlsruhe, Kempten (Allgau), Kiel, Koblenz, Lebach, Leipzig, Ludwigshafen Am Rhein, Luebeck, Magdeburg, Mainz, Mannheim, Marburg, Meschede, Moenchengladbach, Munich, Mutlangen, Oldenburg, Osnabrueck, Paderborn, Regensburg, Schwaebisch Hall, Siegburg, Speyer, Stuttgart, Tuebingen, Ulm, Villingen-Schwenningen, Wuerzburg
Age
18 years and over
People
451 worldwide
Run by
Universitaetsklinikum Heidelberg AöR
See details and how to join2023-507402-13-00 · EU 2023-507402-13-00
No phaseTaking people
Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project
Where
Berlin, Garmisch-Partenkirchen
Age
18 years and over
People
120 worldwide
Run by
Medical University Innsbruck
See details and how to joinNCT06821880
Phase 2/3Taking people
Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients
Where
Aachen, Aschaffenburg, Berlin, Bielefeld, Dachau, Deggendorf, Dortmund, Essen, Frankfurt Am Main, Greifswald, Hamburg, Herne, Jena, Kassel, Lübeck, Muenster, Munich, Nuremberg, Oldenburg, Paderborn, Siegen, Traunstein, Wuerzburg
Age
18 years to 70 years
People
100
Run by
University Hopsital Schleswig Holstein Campus Lübeck
See details and how to joinNCT05665140 · EU 2022-500453-16-00